These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 17211528)

  • 1. Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride.
    Metello J; Nogueira B; Torgal M; Colaço J; Vieira A; Gonçalves V; Retto H
    Int Urogynecol J Pelvic Floor Dysfunct; 2007 Sep; 18(9):1021-5. PubMed ID: 17211528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
    Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
    Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.
    Swift SE; Siami P; Forero-Schwanhaeuser S
    Clin Drug Investig; 2009; 29(5):305-16. PubMed ID: 19366272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of combined low- and standard-dose trospium and solifenacin for moderate overactive bladder symptoms in elderly men and women.
    Kosilov KV; Loparev SA; Ivanovskaya MA; Kosilova LV
    Urol Int; 2014; 93(4):470-3. PubMed ID: 25170796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of solifenacin vs. trospium in the treatment of patients with overactive bladder in the German National Health Service.
    Nazir J; Hart WM
    J Med Econ; 2014 Jun; 17(6):408-14. PubMed ID: 24720775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study on the efficacy of solifenacin succinate in patients with urinary frequency with or without urgency.
    Han JY; Lee KS; Park WH; Park CH; Lee JG; Lee JZ; Kim DY; Na YG; Kwon DD; Choo MS
    PLoS One; 2014; 9(11):e112063. PubMed ID: 25401784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
    Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J;
    BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study.
    Choo MS; Lee JZ; Lee JB; Kim YH; Jung HC; Lee KS; Kim JC; Seo JT; Paick JS; Kim HJ; Na YG; Lee JG
    Int J Clin Pract; 2008 Nov; 62(11):1675-83. PubMed ID: 19143854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
    Herschorn S; Chapple CR; Abrams P; Arlandis S; Mitcheson D; Lee KS; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Robinson D
    BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
    Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
    J Urol; 2009 Dec; 182(6):2825-30. PubMed ID: 19837435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence.
    Kelleher C; Cardozo L; Kobashi K; Lucente V
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 Jun; 17(4):382-8. PubMed ID: 16283422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
    Ho CH; Chang TC; Lin HH; Liu SP; Huang KH; Yu HJ
    J Formos Med Assoc; 2010 Oct; 109(10):702-8. PubMed ID: 20970066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms.
    Abdelhamid MH; Zayed AS; Ghoneima WE; Elmarakbi AA; El Sheemy MS; Aref A; Abdelbary A; Nour HH
    World J Urol; 2017 Aug; 35(8):1261-1268. PubMed ID: 28050642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and safety of solifenacin in daily clinical practice--clinical study phase IV].
    Krhut J; Havránek O; Míka D; Fabisovský M; Valis P
    Ceska Gynekol; 2008 Dec; 73(6):370-5. PubMed ID: 19170373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency.
    Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
    J Urol; 2013 Jan; 189(1 Suppl):S129-34. PubMed ID: 23234618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence.
    Staskin DR; Te AE
    BJU Int; 2006 Jun; 97(6):1256-61. PubMed ID: 16686722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.